About 300 reports

  • HIGH INCIDENCE RATES OF BRAIN ANEURYSM AND CEREBRAL DISORDERS

Currently, SCS systems are used for pain relief, but in the future, they will be also used to treat angina and asthma.

  • Mental Health
  • World
  • DePuy Synthes, Inc.
  • Medtronic, Inc.
  • Stryker Corporation
  • NEURODEGENERATIVE DISORDERS THERAPEUTICS MARKET, COMORBIDITIES ASSOCIATED WITH
  • Mental Health
  • World
  • Biogen Idec Inc.
  • Novartis AG
  • Roche Group

GSK partners with Nuviant Medical to use Diabetes, Asthma and Arthritis.

  • Mental Health
  • Urology Device
  • World
  • Market Size
  • Boston Scientific Corporation
  • Teva Pharmaceutical Industries Limited - Recent Pipeline Updates

Company plans to submit NDA for asthma in 2016.

  • Mental Health
  • United States
  • Auspex Pharmaceuticals, Inc.
  • Cephalon, Inc.
  • ChemGenex Pharmaceuticals Limited

Offers products for asthma and COPD treatment.

  • Mental Health
  • Allergan plc
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • Janssen Biotech, Inc.
  • DECREASE IN FEV1 IN PULMONARY SAFETY TRIALS OF ADASUVE

OF THE ADASUVE-TREATED PATIENTS WITH ASTHMA, ##% DEVELOPED RESPIRATORY-RELATED AES (SUCH AS BRONCHOSPASM, CHEST DISCOMFORT, COUGH, DYSPNEA, THROAT TIGHTNESS, AND WHEEZING) COMPARED TO ##% OF PLACEBO-TREATED PATIENTS.

  • Mental Health
  • World
  • AstraZeneca PLC
  • Lundbeck Inc.
  • Otsuka Pharmaceutical Co., Ltd.

(SD-##) Solidifying Leadership Positions in Core Therapeutic Areas The company" s focus is on its core therapeutic areas of CNS (including MS, neurodegenerative diseases, movement disorders and pain care) and respiratory (including asthma and chronic obstructive pulmonary disease), whe

  • Mental Health
  • United States
  • Market Size
  • Teva Pharmaceutical Industries Ltd.
  • Valeant Pharmaceuticals International, Inc.
  • was 27.29% in 2011 and 24.9% in 2016.
  • Alzheimer's Disease Drugs Sales Volume

High blood pressure and anxiety as well as other respiratory problems like asthma, bronchitis, and poor circulation.

  • Mental Health
  • China
  • Demand
  • Janssen Biotech, Inc.
  • Xian-Janssen Pharmaceutical Ltd.
  • Market drivers

VNS can be used for other neurological disorders, migraine headaches, fibromyalgia, Crohn' s disease, Asthma, Depression, and obsessive-compulsive disorder.

  • Mental Health
  • Forecast
  • Market Size
  • EnteroMedics Inc.
  • LivaNova PLC
  • DECREASE IN FEV1 IN PULMONARY SAFETY TRIALS OF ADASUVE

Of the Adasuve-treated patients with asthma, ##% developed respiratory-related AEs (such as bronchospasm, chest discomfort, cough, dyspnea, throat tightness, and wheezing) compared to ##% of placebo-treated patients.

  • Mental Health
  • Alexza Pharmaceuticals, Inc.
  • Eli Lilly & Co.
  • Lundbeck Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • 4.1 BIBLIOGRAPHY

Depression and comorbidity in community-based patients with epilepsy or asthma.

  • Mental Health
  • France
  • Japan
  • United States
  • Forecast
  • DECREASE IN FEV1 IN PULMONARY SAFETY TRIALS OF ADASUVE

Of the Adasuve-treated patients with asthma, ##% developed respiratory-related AEs (such as bronchospasm, chest discomfort, cough, dyspnea, throat tightness, and wheezing) compared to ##% of placebo-treated patients.

  • Mental Health
  • Alexza Pharmaceuticals, Inc.
  • Eli Lilly & Co.
  • Lundbeck Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • DECREASE IN FEV1 IN PULMONARY SAFETY TRIALS OF ADASUVE

Of the Adasuve-treated patients with asthma, ##% developed respiratory-related AEs (such as bronchospasm, chest discomfort, cough, dyspnea, throat tightness, and wheezing) compared to ##% of placebo-treated patients.

  • Mental Health
  • Alexza Pharmaceuticals, Inc.
  • Eli Lilly & Co.
  • Lundbeck Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • DECREASE IN FEV1 IN PULMONARY SAFETY TRIALS OF ADASUVE

Of the Adasuve-treated patients with asthma, ##% developed respiratory-related AEs (such as bronchospasm, chest discomfort, cough, dyspnea, throat tightness, and wheezing) compared to ##% of placebo-treated patients.

  • Mental Health
  • Alexza Pharmaceuticals, Inc.
  • Eli Lilly & Co.
  • Lundbeck Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • DECREASE IN FEV1 IN PULMONARY SAFETY TRIALS OF ADASUVE

OF THE ADASUVE-TREATED PATIENTS WITH ASTHMA, ##% DEVELOPED RESPIRATORY-RELATED AES (SUCH AS BRONCHOSPASM, CHEST DISCOMFORT, COUGH, DYSPNEA, THROAT TIGHTNESS, AND WHEEZING) COMPARED TO ##% OF PLACEBO-TREATED PATIENTS.

  • Mental Health
  • Alkermes plc
  • Janssen Biotech, Inc.
  • Lundbeck Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Alzheimer's Disease Drugs Sales Volume
  • was 27.29% in 2011 and 24.9% in 2016.

High blood pressure and anxiety as well as other respiratory problems like asthma, bronchitis, and poor circulation.

  • Mental Health
  • China
  • Guizhou Yibai Pharmaceutical Co., Ltd.
  • Novartis AG
  • Shandong Qilu Pharmaceutical Co., Ltd

asthma; under this segment, the company provides medicines to treat HIV, lupus, benign prostatic hyperplasia, type ## diabetes, bacterial infections, and others; the company also provides extensive portfolio of more than ## pediatric, adolescent, adult, and travel vaccines Consumer healthcar

  • Mental Health
  • Actavis plc
  • Bristol-Myers Squibb Company
  • Eli Lilly & Co.
  • GlaxoSmithKline plc
  • GLOBAL SALES FORECASTS ($M) FOR NERVENTRA, 2014-2024
  • FORECASTS THE GLOBAL SALES OF NERVENTRA DURING 2014-2024.

MASITINIB IS CURRENTLY BEING EXPLORED FOR THE TREATMENT OF ALZHEIMER' S DISEASE, RA, ASTHMA, AMYOTROPHIC LATERAL SCLEROSIS (ALS), CROHN' S DISEASE, AND VARIOUS CANCERS.

  • Mental Health
  • World
  • Forecast
  • Biogen Idec Inc.
  • Novartis AG

CVT-## WILL BE TAKEN AS NEEDED, SIMILAR TO A " RESCUE INHALER, " WHICH IS COMMON IN THE ASTHMA MARKET.

  • Mental Health
  • Forecast
  • Merck & Co., Inc.
  • Novartis AG
  • Roche Group
  • 4.3.4 AZD3293 - ASTRAZENECA

In addition to mild-to-moderate AD, masitinib is being trialed for multiple sclerosis, asthma and various cancers.

  • Mental Health
  • Asia
  • World
  • Forecast
  • Biogen Idec Inc.

asthma and chronic obstructive pulmonary disease in Europe February 2014: Receives full approval of SYNRIBO (omacetaxine mepesuccinate) for injection January 2014: The US FDA approves the company' s supplemental NDA for three-times-a-week Copaxone ## mg per ml, a new dose of Copaxone Ja

  • Mental Health
  • Biogen Idec Inc.
  • Merck Serono S.A.
  • Novartis AG
  • Pfizer Inc.
  • Alzheimer's Disease Market, Global, AZD3293 Market Forecast ($m), 2019-2021
  • 5.4.4 AB1010 - AB SCIENCE

Besides mild-to-moderate AD, masitinib is being trialed for multiple sclerosis, asthma and various cancers.

  • Mental Health
  • World
  • Forecast
  • Market Size
  • Eisai Co., Ltd.
  • 3.1 ETIOLOGY AND PATHOPHYSIOLOGY

MDD HAS ALSO BEEN LINKED TO CARDIOVASCULAR DISEASE, DIABETES, ASTHMA, OBESITY, AND SEVERAL ADVERSE HEALTH BEHAVIORS, SUCH AS SMOKING, PHYSICAL INACTIVITY, AND HIGH ALCOHOL INTAKE (STRINE ET AL., 2008).

  • Mental Health
  • Alkermes plc
  • Allergan plc
  • Lundbeck Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • PRODUCT PROFILE - AB-1010
  • PRESENTS A PRODUCT PROFILE OF AB-1010.

AB-## IS CURRENTLY BEING EXPLORED IN THE TREATMENT OF RHEUMATOID ARTHRITIS (RA), MULTIPLE SCLEROSIS (MS), ASTHMA, AND SEVERAL TYPES OF CANCERS, IN ADDITION TO BEING INVESTIGATED AN ONGOING PHASE III STUDY IN PATIENTS WITH MILD TO MODERATE AD.

  • Mental Health
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • Merck & Co., Inc.
  • Roche Group

asthma and chronic obstructive pulmonary disease in Europe February 2014: Receives full approval of SYNRIBO (omacetaxine mepesuccinate) for injection January 2014: The US FDA approves the company' s supplemental new drug application for three-times-aweek Copaxone ##mg/ mL, a new dos

  • Mental Health
  • United States
  • Biogen Idec Inc.
  • Merck Serono S.A.
  • Novartis AG

It has other respiratory products in the pipeline such as mepolizumab, an investigational anti-IL## monoclonal antibody for the treatment of severe eosinophilic asthma.

  • Mental Health
  • Azevan Pharmaceuticals, Inc.
  • GlaxoSmithKline plc
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.

asthma; under this segment, the company provides medicines to treat HIV, lupus, benign prostatic hyperplasia, type ## diabetes, bacterial infections, and others; the company also provides extensive portfolio of more than ## paediatric, adolescent, adult, and travel vaccines Consumer healthca

  • Mental Health
  • World
  • Boehringer Ingelheim GmbH
  • GlaxoSmithKline plc
  • XenoPort, Inc.

asthma from the US FDA Pulmonary Drugs Advisory Committee May ##, 2015: Announces the submission of a regulatory application to the Japanese Ministry of Health, Labour and Welfare for mepolizumab in treating individuals with severe eosinophilic asthma May ##, 2015: Presents two abs

  • Mental Health
  • Europe
  • Eisai Co., Ltd.
  • GlaxoSmithKline plc
  • Pfizer Inc.

GSK has a diversified portfolio of products and provides assistance in treating major diseases such as asthma, cancer, infections, mental health, diabetes, and digestive conditions, and in viral diseases.

  • Mental Health
  • United States
  • Actavis plc
  • Eli Lilly & Co.
  • GlaxoSmithKline plc

GSK has a diversified portfolio of products and provides assistance in treating major diseases such as asthma, cancer, infections, mental health, diabetes, and digestive conditions, and in viral diseases.

  • Mental Health
  • World
  • Eli Lilly & Co.
  • GlaxoSmithKline plc
  • Pfizer Inc.